ALLR

The stock price of Allarity Therapeutics, Inc. has been impacted by several key events over the past six months. On March 6, 2026, Allarity closed a $20 million non-convertible debt financing with Streeterville Capital, resulting in a +21.57% increase in the stock price. On March 31, 2026, the company reported its full-year 2025 financial results, which included its first reported revenue and a significantly reduced net loss, followed by a +4.81% increase in the stock price. On April 27, 2026, Allarity Therapeutics announced that its Stenoparib DRP® Test received a Notice of Allowance from the U.S. Patent and Trademark Office, leading to a +2.24% increase in the stock price. On May 5, 2026, the company announced it was advancing Stenoparib toward pivotal development with a Phase 3 manufacturing campaign, coinciding with a +12.00% increase in the stock price. On May 8, 2026, news that Allarity Therapeutics' CEO would present at the Precision Medicine Forum Europe 2026 in Stockholm was associated with a +3.33% increase in the stock price. Overall, the stock has shown a positive trend, increasing by 43.5% year-to-date as of May 9, 2026, and a 40.78% increase over the past year as of May 6, 2026.